- Key Takeaways
- Spravato reimbursement rate depends on dose, payer type, and procurement model, with Medicare and commercial payers paying materially different amounts per session.
- Medicare reimburses G2082 at a national average of $952.59 and G2083 at approximately $1,356.08 for 2026, with rates varying by MAC region.
- G2082 is a bundled HCPCS code covering drug cost, physician supervision, and the mandatory two-hour observation for sessions involving up to 56 mg esketamine.
- Medicare Advantage plans follow private insurer rules, not traditional Medicare, so benefits verification is required separately for each MA plan at patient onboarding.
- CMS finalized two 2026 conversion factors, $33.57 for qualifying APM services and $33.40 for all others, directly affecting Spravato G-code payment calculations.
An estimated 2.8 million U.S. adults with major depressive disorder meet the criteria for treatment-resistant depression, representing nearly 31% of all medicated MDD patients. For the practices now offering Spravato (esketamine) as an FDA-approved treatment for this population, the clinical value is clear. The revenue picture is less so.
Here is the gap that gets practices into trouble: the Spravato reimbursement rate a practice expects and the amount it actually receives are frequently not the same number. Drug cost is committed before a single claim is filed. More than 32% of Spravato claims are denied on first submission without specialist billing management, and each denial represents a session in which $600 to over $1,000 in drug cost is already spent. Providers who run a Spravato program without understanding exactly how reimbursement works, what each payer pays for each code, and where the most common payment gaps occur end up absorbing losses they had no reason to take.
What Spravato Treatment Actually Involves
Spravato (esketamine nasal spray) is FDA-approved for adults with treatment-resistant depression (TRD) and major depressive disorder with acute suicidal ideation or behavior (MDD-SIBA). It is not a take-home prescription. Every session must be administered in a REMS-certified clinical setting under direct physician or qualified healthcare professional supervision, followed by a mandatory two-hour post-administration observation period.
The standard treatment course involves two sessions per week for the first month, moving to weekly and then biweekly sessions across an optimization and maintenance phase. Most patients complete at least 11 sessions in the first two months. This is relevant to reimbursement because the buy-and-bill drug cost is incurred at every session, and the number of sessions before payer payment is received makes cash flow management a critical operational variable for any practice running a Spravato program.
The therapy has two FDA-approved indications, each with specific ICD-10 coding requirements. TRD is typically coded as F32.2 or F33.2; MDD with acute suicidal ideation uses F32.2 with supporting documentation of clinical urgency. Payer coverage criteria map to these indications, and misapplied diagnosis codes are among the most consistent drivers of prior authorization denial.
How Spravato Reimbursement Works
Spravato reimbursement operates on two parallel tracks, and the path a practice takes depends on the payer and the procurement model.
Under the buy-and-bill model, the practice purchases the drug directly from a REMS-certified specialty distributor, administers it on-site, and then bills the payer for both the drug and the clinical services as a bundled claim. Under the specialty pharmacy pathway, a pharmacy supplies the drug, and the practice bills only for administration and observation services.
For Medicare and most commercial payers following Medicare’s billing structure, the buy-and-bill model uses two bundled HCPCS codes: G2082 for sessions involving up to 56 mg of esketamine and G2083 for sessions above 56 mg. Both codes bundle the drug cost, physician supervision, and the two-hour observation into a single payment. This is a critical distinction: when billing G2082 or G2083, you cannot separately bill E/M codes or prolonged service codes on the same date of service. The bundle is the claim.
Effective January 1, 2026, CMS replaced S0013 with J0013 as the permanent HCPCS J-code for esketamine nasal spray. J0013 is reported in 1 mg increments, billed in units equal to the milligrams administered. However, J0013 is not payable by Medicare; it applies to Medicaid agencies and applicable commercial payers. For Medicare patients, G2082 or G2083 remains the correct pathway. For commercial payers that have not yet adopted the G-code structure, J0013 paired with E/M and observation codes may be required. Payer-specific verification at onboarding is not optional.
Calculating the Cost of Spravato: Drug and Monitoring
Before a single dollar of reimbursement arrives, the practice has already absorbed significant cost. Understanding that cost is the foundation of any informed Spravato reimbursement conversation.
Drug Acquisition Cost (Buy-and-Bill)
The per-dose cost of Spravato under the buy-and-bill model depends on the dose strength. The 56 mg dose (two nasal spray devices) runs approximately $882 at current distributor pricing, while the 84 mg dose (three devices) runs approximately $1,319. These costs are incurred at the time of purchase from a REMS-certified specialty distributor before any claim is filed. For a standard eight-session induction month, the drug acquisition cost alone can reach $7,000 to $10,000 before the first reimbursement check arrives.
Monitoring and Administration Cost
Beyond the drug itself, each session requires two hours of clinical staff time for patient observation, vital sign monitoring, and REMS-required documentation. Staffing and facility overhead for each session is estimated at $200 to $400, depending on site-of-care. This is not separately billable under the G-code bundle, making operational efficiency a direct variable in program profitability.
Total Practice Revenue at Risk Per Induction Course
For a patient completing the standard eight-session induction phase at the 56 mg dose, the practice commits approximately $7,000 to $8,000 in drug cost before the payer pays. A single denied claim in that sequence does not just delay revenue; it creates a loss that may not be recoverable without a formal appeal.
2026 Medicare Benchmarks by Code
The national average Medicare reimbursement rate for G2083 in 2026 is approximately $1,356.08, while G2082 reimburses at a lower rate reflecting the reduced drug cost at the 56 mg dose. Published benchmarks from billing sources tracking the CMS Physician Fee Schedule place G2082 at a national average of approximately $952.59 for 2026.
These are non-facility rates. Reimbursement will vary by Medicare Administrative Contractor (MAC) region, meaning a practice in one geographic area may receive a materially different payment than a practice in another. Practices should verify their specific MAC’s payment rates through the CMS Physician Fee Schedule Look-up Tool before modeling program revenue.
A few selection rules that frequently drive errors: G2082 and G2083 apply only to established patients. CMS rules prohibit billing either code for new patient visits, which require a separate E/M code. Additionally, if the supervising healthcare provider does not also supply the drug, they cannot report G2082 or G2083.
The 2026 CMS Physician Fee Schedule final rule established two conversion factors for CY 2026: $33.57 for services under qualifying Alternative Payment Models and $33.40 for all other services, representing increases of 3.83% and 3.26% respectively from prior year levels.
Commercial Payer Ranges and How They Compare
Commercial payer reimbursement for Spravato does not follow a single national standard. Rates are negotiated at the contract level and vary significantly by payer, plan type, and geographic market.
As a general benchmark, major commercial payers tend to reimburse at rates between 90% and 130% of Medicare for the G-code bundle, though some payers have negotiated rates outside this range. Reported commercial reimbursement for G2082 from major payers including BCBS, UHC, Aetna, and Cigna averages approximately $857. This is notably lower than the Medicare rate for the same code, which is a common source of surprise for practices assuming commercial payers pay more.
Payer-specific coverage structures add further complexity. Several major commercial payers have explicitly bundled E/M codes into G2082 and G2083, meaning that billing a separate evaluation and management code on the same date will be denied regardless of modifier. This applies to both standard commercial plans and Medicare Advantage plans for those payers.
Some commercial payers also remain on the S0013 coding structure for dates of service prior to their own code transition. Practices must maintain payer-specific coding configurations rather than applying a single billing protocol across all payers. The risk of using the wrong code on the wrong payer is an automatic denial.
The Janssen Patient Assistance Program and Its Impact on Practice Revenue
For commercially insured patients, Janssen Pharmaceuticals offers the Spravato withMe Savings Program. Eligible patients can reduce their out-of-pocket cost to as little as $10 per treatment session, with a maximum annual savings limit of $8,150 per calendar year. The program requires active commercial insurance coverage; it does not apply to Medicare, Medicaid, or uninsured patients.
The practical impact on practice revenue depends on whether the program affects payer behavior. For practices, it functions primarily as a patient retention tool. A patient who cannot afford the cost-share may discontinue treatment; the savings program reduces that risk. However, it does not change what the payer pays the practice, and it does not replace prior authorization. Practices should still verify that coverage is active and that authorization is in place before each phase of treatment.
For Medicare and Medicaid patients, no manufacturer assistance is available. Medicare covers Spravato under Part B, with patients responsible for the annual Part B deductible (approximately $257 for 2025) and 20% coinsurance after the deductible is met, unless supplemental coverage applies. Medicaid coverage varies significantly by state; some states fully cover Spravato while others do not cover it at all, and documentation requirements for Medicaid prior authorization can be more intensive than those for commercial payers.
- Neolytix • Spravato Billing
Spravato Billing
Neolytix manages REMS compliance and buy-and-bill RCM as one integrated workstream, with NDC-specific claim workflows, PA expiration tracking, and contracted SLAs that keep denial rates below 5%.
Why Your Reimbursement May Be Lower Than Expected
Even when claims are submitted correctly, several structural factors cause practices to receive less than the benchmark rate or nothing at all.
Prior authorization lapses. Most payers authorize a defined number of sessions at a time, typically covering the induction phase or a set number of maintenance sessions. When that authorization expires and the practice does not proactively renew it, the next session bills without active coverage. The claim is denied, and because the service has already been delivered, the appeal window becomes the only recovery pathway. Proactive PA tracking by session count is not optional; it is a financial control.
REMS documentation gaps. Patient Monitoring Form submission is required within a specific window after each session. When those forms are late or missing, payers use the discrepancy as grounds for denial. For more detail on REMS documentation requirements and how they connect to billing, see Neolytix’s complete Spravato billing and coding guide.
NDC mismatches on drug claims. Under the buy-and-bill model, the NDC number from the specific lot purchased must appear on the J0013 claim. A mismatch between the NDC on the claim and the payer’s records for that patient triggers an automatic denial. This requires lot-level tracking in the practice’s billing workflow.
Undercoding administration services. Practices sometimes default to lower-complexity E/M codes when documentation would support a higher level, or fail to capture all qualifying service components in settings where E/M codes are separately billable. This is recoverable through prospective clinical documentation improvement but is rarely caught without a dedicated Spravato coding audit.
Underpayment without follow-up. When a payer reimburses below the contracted rate, the claim technically processes without a denial. Without systematic underpayment monitoring, these amounts accumulate quietly. The recovery window is typically governed by the contract’s timely dispute clause, which means unmonitored underpayments become permanent write-offs.
Documentation That Drives Reimbursement
Every payer audit, post-payment review, and prior authorization denial ultimately comes back to the same question: does the record prove that this patient needed this treatment, administered exactly this way, on this date? For Spravato, that question carries more financial weight than it does for nearly any other outpatient behavioral health service, because the drug cost is already spent before the claim is reviewed.
Documentation is not a compliance formality for Spravato programs. It is the mechanism by which you get paid and stay paid.
Building the Medical Necessity Record
The core of a defensible Spravato claim is a chart that walks the reviewer through three things without ambiguity: the patient met the clinical criteria for TRD or MDD-SIBA, the provider and facility were REMS-certified and qualified to administer the drug, and the treatment was delivered safely and in accordance with FDA guidelines.
That means the record needs to carry confirmed diagnosis using a validated assessment tool such as the PHQ-9 or MADRS, documented failure of at least two antidepressants at adequate doses and for adequate durations, a current treatment plan specifying the phase of treatment and dosing schedule, and a Letter of Medical Necessity signed by the supervising clinician. The LMN should not be a template. It should be a narrative that connects the patient’s treatment history to the specific clinical rationale for Spravato, written as though someone will scrutinize it.
At re-authorization, the LMN needs to be updated, not recycled. A maintenance phase re-auth that resubmits the original induction-phase LMN without any reference to clinical progress is one of the more common triggers for a medical necessity denial that practices could have avoided.
Session-Level Charting That Holds Up
Each session note needs to function as a standalone record of a compliant Spravato administration. That means logging the drug administered (dose in milligrams, method, whether self-administered by the patient or staff-assisted), the precise start and end times of the two-hour observation window, vital signs at regular intervals throughout the monitoring period, and any adverse events including their onset, severity, any clinical interventions taken, and the patient’s status at discharge.
The observation start and end times matter beyond compliance. For any payer that separately evaluates observation time before paying a bundled G-code, a chart that shows an administration time and nothing else does not support the claim. This is a specific and recoverable documentation gap, but it has to be caught before the claims go out, not after a pattern of denials.
Connecting Diagnosis to Code
A chart that documents everything correctly but does not align with the codes on the claim will still generate denials. The ICD-10 diagnosis codes must match every line on the claim, including the drug code, the procedure code, and any separately billed services. The primary diagnosis is listed first and must be supported by clinical notes and validated assessment scores at the encounter level. For TRD, F32.2 and F33.2 are the standard codes. For MDD-SIBA, documentation must reflect acute suicidal ideation or behavior as the primary clinical driver.
Payer coverage policies vary in which ICD-10 codes they will accept for Spravato authorization and claims. Verifying those allowable codes at the payer level before submission prevents a category of denials that have nothing to do with clinical quality and everything to do with administrative misalignment.
The documentation standard that prevents denials is the same standard that survives an audit. A Spravato record should read as a complete clinical and administrative story, from diagnosis through discharge, every session, every time.
Why a Specialized RCM Partner Changes the Outcome
General RCM vendors are not built for Spravato. The buy-and-bill workflow, REMS compliance integration, dual-benefit path verification, NDC-specific drug claim construction, and proactive PA management each require Spravato-specific processes that most billing vendors have not built.
The downstream cost of using a general vendor for Spravato billing shows up in denial rates, underpayment, and lapsed authorizations. It rarely shows up as a line item until the practice runs an A/R analysis and finds sessions that were never recovered.
A purpose-built Spravato billing program addresses every stage of the workflow, from benefit path confirmation and benefits verification before the first session to REMS cross-check at claim submission and systematic underpayment recovery in A/R. The operational standard for a specialist program is a denial rate below 5% and a first-pass rate above 98% on Spravato-coded claims.
If your practice is building or auditing a Spravato program, Neolytix’s Spravato billing services include REMS and RCM managed as a single integrated workstream, with a Power BI dashboard from day one and contracted performance SLAs. You can also review the behavioral health AR recovery case study to see what structured Spravato RCM management looks like in practice.
Conclusion
The Spravato reimbursement rate a practice actually collects in 2026 is determined by far more than the Medicare fee schedule. Drug acquisition cost, benefit path, payer-specific coding rules, prior authorization management, REMS documentation, and underpayment recovery all shape what lands in the practice’s bank account. The gap between what a session should pay and what an unmanaged program actually collects can be significant enough to make a financially viable Spravato program a recurring loss.
Understanding these variables before the first session, not after the first denial, is what separates programs that sustain themselves from those that quietly absorb costs until the program becomes unviable.
- Neolytix • Contact Us
Schedule a Consultation
Neolytix partners with healthcare organizations across revenue cycle, credentialing, and administrative operations ,14+ years of expertise and AI-enabled automation to reduce inefficiencies and drive sustainable growth.
Sources
Zhdanava M, Pilon D, Ghelerter I, et al. The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States. Journal of Clinical Psychiatry. 2021. Available at: https://pubmed.ncbi.nlm.nih.gov/33989464/
Centers for Medicare and Medicaid Services. Calendar Year (CY) 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F). October 31, 2025. Available at: https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2026-medicare-physician-fee-schedule-final-rule-cms-1832-f
Centers for Medicare and Medicaid Services. Article: Billing and Coding: Esketamine (A59249). Available at: https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=59249
Centers for Medicare and Medicaid Services. Physician Fee Schedule Look-up Tool. Available at: https://www.cms.gov/medicare/physician-fee-schedule/search/overview
National Library of Medicine / PubMed Central. Economic Burden of Treatment-Resistant Depression on the U.S. Health Care System. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10398213/
National Library of Medicine / PubMed Central. The Individual and Societal Burden of Treatment-Resistant Depression: An Overview. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC11008705/
Frequently Asked Questions
Can a Spravato practice accept Medicare Advantage patients the same way it accepts traditional Medicare?
Not automatically. Medicare Advantage plans are administered by private insurers and may have coverage criteria, PA requirements, and coding rules that differ from traditional Medicare. Some MA plans have adopted commercial payer bundling edits that deny separate E/M codes, while others follow the CMS G-code structure. Benefits verification for each MA plan is required at patient onboarding.
What happens to pending prior authorizations if a payer changes its Spravato coverage policy mid-treatment?
Active prior authorizations are generally honored through their expiration date, but re-authorization requests will be evaluated under the new policy. Practices should monitor payer policy updates and flag any patients whose treatment is approaching the re-authorization window, particularly those enrolled in commercial plans known for periodic coverage policy revisions.
Is Spravato reimbursed differently for maintenance phase sessions than induction phase sessions?
The billing codes (G2082/G2083) and rates are the same regardless of treatment phase. The difference lies in session frequency and authorization. Most payers authorize the induction phase separately from the maintenance phase, and some apply different step therapy or clinical progress documentation requirements for maintenance re-authorization. An induction-phase authorization does not automatically carry through to maintenance, and billing maintenance sessions without active authorization is a common source of denials.
If a patient discontinues Spravato after induction, can the practice recover reimbursement for partially completed sessions?
Completed sessions that were properly documented, authorized, and billed are fully reimbursable regardless of whether the patient continues treatment. The risk arises when a patient discontinues during an active authorization cycle and the practice has already purchased drug for future sessions under the buy-and-bill model. The purchased drug inventory cost is not recoverable from the payer and becomes a practice liability.
